Controlled Trial of ABELADRUG200 in Closed, Severe Head Injury — ABELADRUG200  

Severe Head Trauma Clinical Trial

Official title: Phase 1/2 Multicenter, Randomized, Controlled Trial of ABELADRUG200 in Closed, Severe Head Injury

Status Recruiting

Clinical Trial Summary

This is a randomized, controlled clinical trial at three sites to determine the safety and preliminary efficacy of the study drug to treat severe head trauma (GCS 4-8). It is hypothesized that the drug may lower pressure in the brain, reduce mortality and the patient may have improved neurological function following treatment.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Craniocerebral Trauma
• Severe Head Trauma

• NCT number: NCT00810940
• Study type: Interventional
• Source: Abela Pharmaceuticals, Inc.
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: October 2010
• Completion date: December 2011